BlackSky Technology Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BlackSky Technology Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $0 | May 12, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $106.58M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $102.09M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $94.49M | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | $21.26M | Nov 8, 2023 |
| FY2023 | Jun 30, 2023 | $19.33M | Aug 9, 2023 |
| FY2023 | Mar 31, 2023 | $18.40M | May 10, 2023 |
| FY2023 | Dec 31, 2022 | $65.35M | Mar 20, 2024 |
| FY2023 | Sep 30, 2022 | $16.94M | Nov 8, 2023 |
| FY2023 | Jun 30, 2022 | $15.10M | Aug 9, 2023 |
| FY2023 | Mar 31, 2022 | $13.90M | May 10, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($70.26M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($57.22M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($53.86M) | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | $675.0K | Nov 8, 2023 |
| FY2023 | Jun 30, 2023 | ($33.43M) | Nov 8, 2023 |
| FY2023 | Mar 31, 2023 | ($17.32M) | Nov 8, 2023 |
| FY2023 | Dec 31, 2022 | ($74.17M) | Mar 20, 2024 |
| FY2023 | Sep 30, 2022 | ($13.09M) | Nov 8, 2023 |
| FY2023 | Jun 30, 2022 | ($26.28M) | Nov 8, 2023 |
| FY2023 | Mar 31, 2022 | ($19.99M) | Nov 8, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($46.90M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($44.29M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($55.98M) | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | ($14.52M) | Nov 8, 2023 |
| FY2023 | Jun 30, 2023 | ($19.92M) | Aug 9, 2023 |
| FY2023 | Mar 31, 2023 | ($16.90M) | May 10, 2023 |
| FY2023 | Dec 31, 2022 | ($86.55M) | Mar 20, 2024 |
| FY2023 | Sep 30, 2022 | ($19.41M) | Nov 8, 2023 |
| FY2023 | Jun 30, 2022 | ($21.71M) | Aug 9, 2023 |
| FY2023 | Mar 31, 2022 | ($27.14M) | May 10, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $433.0K | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.34M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $643.0K | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | $133.0K | Nov 8, 2023 |
| FY2023 | Jun 30, 2023 | $176.0K | Aug 9, 2023 |
| FY2023 | Mar 31, 2023 | $216.0K | May 10, 2023 |
| FY2023 | Dec 31, 2022 | $739.0K | Mar 20, 2024 |
| FY2023 | Sep 30, 2022 | $197.0K | Nov 8, 2023 |
| FY2023 | Jun 30, 2022 | $106.0K | Aug 9, 2023 |
| FY2023 | Mar 31, 2022 | $146.0K | May 10, 2023 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $87.40M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $74.07M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $72.62M | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | $17.57M | Nov 8, 2023 |
| FY2023 | Jun 30, 2023 | $18.77M | Aug 9, 2023 |
| FY2023 | Mar 31, 2023 | $18.95M | May 10, 2023 |
| FY2023 | Dec 31, 2022 | $79.67M | Mar 20, 2024 |
| FY2023 | Sep 30, 2022 | $18.76M | Nov 8, 2023 |
| FY2023 | Jun 30, 2022 | $17.74M | Aug 9, 2023 |
| FY2023 | Mar 31, 2022 | $22.54M | May 10, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($28.31M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($6.38M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($17.42M) | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | ($15.80M) | Nov 8, 2023 |
| FY2023 | Jun 30, 2023 | ($15.63M) | Aug 9, 2023 |
| FY2023 | Mar 31, 2023 | ($16.60M) | May 10, 2023 |
| FY2023 | Dec 31, 2022 | ($44.46M) | Mar 20, 2024 |
| FY2023 | Sep 30, 2022 | ($39.43M) | Nov 8, 2023 |
| FY2023 | Jun 30, 2022 | ($27.79M) | Aug 9, 2023 |
| FY2023 | Mar 31, 2022 | ($12.68M) | May 10, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $386.25M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $254.15M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $224.07M | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | $212.79M | Nov 8, 2023 |
| FY2023 | Jun 30, 2023 | $228.09M | Aug 9, 2023 |
| FY2023 | Mar 31, 2023 | $241.25M | May 10, 2023 |
| FY2023 | Dec 31, 2022 | $234.09M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $305.76M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $119.92M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $318.25M | May 12, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $291.37M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $160.16M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $130.91M | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | $120.66M | Nov 8, 2023 |
| FY2023 | Jun 30, 2023 | $139.54M | Aug 9, 2023 |
| FY2023 | Mar 31, 2023 | $122.34M | May 10, 2023 |
| FY2023 | Dec 31, 2022 | $112.22M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $126.14M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $152.73M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $33.15M | May 12, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $94.88M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $93.99M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $93.16M | Mar 17, 2026 |
| FY2023 | Sep 30, 2023 | $92.14M | Nov 8, 2023 |
| FY2023 | Jun 30, 2023 | $88.55M | Nov 8, 2023 |
| FY2023 | Mar 31, 2023 | $118.91M | Nov 8, 2023 |
| FY2024 | Dec 31, 2022 | $121.87M | Mar 20, 2025 |
| FY2023 | Sep 30, 2022 | $133.36M | Nov 8, 2023 |
| FY2023 | Jun 30, 2022 | $143.54M | Nov 8, 2023 |
| FY2023 | Mar 31, 2022 | $166.89M | Nov 8, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.28M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $10.26M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $9.39M | Mar 17, 2026 |
| FY2023 | Sep 30, 2023 | $9.39M | Nov 8, 2023 |
| FY2023 | Jun 30, 2023 | $9.39M | Aug 9, 2023 |
| FY2023 | Mar 31, 2023 | $9.39M | May 10, 2023 |
| FY2024 | Dec 31, 2022 | $9.39M | Mar 20, 2025 |
| FY2022 | Dec 31, 2021 | $9.39M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $9.39M | Mar 31, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($726.45M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($656.19M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($598.97M) | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | ($595.18M) | Nov 8, 2023 |
| FY2023 | Jun 30, 2023 | ($595.86M) | Aug 9, 2023 |
| FY2023 | Mar 31, 2023 | ($562.43M) | May 10, 2023 |
| FY2023 | Dec 31, 2022 | ($545.11M) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($470.91M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($223.98M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($7.21M) | May 12, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.45M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $13.06M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $32.82M | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | $32.14M | Nov 8, 2023 |
| FY2023 | Jun 30, 2023 | $41.10M | Aug 9, 2023 |
| FY2023 | Mar 31, 2023 | $56.96M | May 10, 2023 |
| FY2023 | Dec 31, 2022 | $34.18M | Mar 20, 2024 |
| FY2023 | Sep 30, 2022 | $37.20M | Nov 8, 2023 |
| FY2023 | Jun 30, 2022 | $64.83M | Aug 9, 2023 |
| FY2023 | Mar 31, 2022 | $135.89M | May 10, 2023 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $201.12M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $107.66M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $83.50M | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | $79.47M | Nov 8, 2023 |
| FY2023 | Jun 30, 2023 | $79.41M | Aug 9, 2023 |
| FY2023 | Dec 31, 2022 | $76.22M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $71.41M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $101.61M | Mar 31, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | 0 | Nov 8, 2023 |
| FY2023 | Jun 30, 2023 | 0 | Aug 9, 2023 |
| FY2023 | Mar 31, 2023 | 0 | May 10, 2023 |
| FY2023 | Dec 31, 2022 | 0 | Mar 20, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Nov 8, 2023 |
| FY2023 | Jun 30, 2022 | 0 | Aug 9, 2023 |
| FY2023 | Mar 31, 2022 | 0 | May 10, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | 0 | Nov 8, 2023 |
| FY2023 | Jun 30, 2023 | 0 | Aug 9, 2023 |
| FY2023 | Mar 31, 2023 | 0 | May 10, 2023 |
| FY2023 | Dec 31, 2022 | 0 | Mar 20, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Nov 8, 2023 |
| FY2023 | Jun 30, 2022 | 0 | Aug 9, 2023 |
| FY2023 | Mar 31, 2022 | 0 | May 10, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 35.93M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | 30.66M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | 17.86M | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | 140.54M | Nov 8, 2023 |
| FY2023 | Jun 30, 2023 | 138.41M | Aug 9, 2023 |
| FY2023 | Mar 31, 2023 | 136.84M | May 10, 2023 |
| FY2023 | Dec 31, 2022 | 119.51M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | 114.45M | Mar 23, 2023 |
| FY2022 | Sep 8, 2021 | 31.63M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 34.69M | Mar 31, 2022 |